PD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1), and PDGFRβ (platelet-derived growth factor receptor β) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). PD 166285 also inhibits the checkpoint kinases Wee1 and MYT1 (Myt1), abolishes Cdc2 phosphorylation in numerous tumor cell lines, and abrogates the G2 checkpoint. PD 166285 is an RTK inhibitor with broad-spectrum properties and displays anti-angiogenic activity and anti-tumor efficacy when used with PDT (photodynamic therapy). PD 166285 is an inhibitor of EGFR.
Star, W., et al.: Cancer Res., 46, 2532 (1986), Sawutz, D., et al.: Biochem. Pharm., 51, 1631 (1996), Voest, E., et al.: Anti-Cancer Drugs, 7, 723 (1996), Connolly, C., et al.: Bioorg. Med. Chem. Lett., 7(18), 2415 (1997), Hamby, J., et al.: J. Med. Chem., 40, 2296 (1997)
圣克鲁斯生物技术在生物医药研究市场的产品开发方面处于世界领先地位。欢迎 致电我们的免费电话(021) 800-820-8626。 版权 ©, 2007-2021圣克鲁斯生物技术。版权所有。“Santa Cruz Biotechnology”,圣克鲁斯生物技 术的 商标,“Santa Cruz Animal Health”,“San Juan Ranch”,“Supplement of Champions”,San Juan Ranch的商标,“Ultracruz”,“Chemcruz”,“Immunocruz”,“Exactacruz”和“EZ Touch”都是圣克鲁斯生物技术的注册商标。所有的商标都归其各自拥有者所有。